Services

Toxicology

Pharmacology

Animal Model Development

Medical Device Testing

In Vitro Screening

Custom Assay Development

Vivarium Rental

Histology

Therapeutic Areas

Oncology

Immunology & Inflammation

Neurology / CNS

Cardiovascular

Dermatology & Wound Healing

Metabolism

Gastroenterology

Hepatology

Pulmonology

Infectious Diseases & Sepsis

Musculoskeletal

Nephrology & Urology

Species

Non-human Primates

Dogs

Minipigs / Pigs

Rabbits

Mice

Rats

Sheep

Guinea Pigs

Hamsters

Other Species

Capabilities

GLP / IND-Enabling Studies

Small and Large Animal Housing

Bioanalytical Platforms

About

News

Contact

Careers

Request a Quote

Logo
☰
  • Services ⌄
    • Toxicology
    • Pharmacology
    • Animal Model Development
    • Medical Device Testing
    • In Vitro Screening
    • Custom Assay Development
    • Vivarium Rental
    • Histology
  • Therapeutic Areas ⌄
    • Oncology
    • Immunology & Inflammation
    • Neurology / CNS
    • Cardiovascular
    • Dermatology & Wound Healing
    • Metabolism
    • Gastroenterology
    • Hepatology
    • Pulmonology
    • Infectious Diseases & Sepsis
    • Musculoskeletal
    • Nephrology & Urology
  • Species ⌄
    • Non-human Primates
    • Dogs
    • Minipigs / Pigs
    • Rabbits
    • Mice
    • Rats
    • Sheep
    • Guinea Pigs
    • Hamsters
    • Other Species
  • Capabilities ⌄
    • GLP / IND-Enabling Studies
    • Small and Large Animal Housing
    • Bioanalytical Platforms
  • About ⌄
    • News
  • Contact ⌄
    • Careers
    • Request a Quote

AdvaMed, MDMA Support, but Express Concerns Over CMS Coverage of Breakthrough Devices

  • Post author:PacConAdmin
  • Post published:August 31, 2023
  • Post category:Uncategorized

AdvaMed and the Medical Device Manufacturers Association (MDMA) commented this week on a CMS notice expediting Medicare coverage of emerging technologies, urging swift acceptance of the program, but also arguing…

Continue ReadingAdvaMed, MDMA Support, but Express Concerns Over CMS Coverage of Breakthrough Devices

Sen. Warren, Rep. Jayapal Ask FDA to Close Loopholes That Keep Generics Off the Market

  • Post author:PacConAdmin
  • Post published:August 31, 2023
  • Post category:Uncategorized

Sen. Elizabeth Warren (D-Mass.) and Rep. Pramila Jayapal (D-Wash.) want the FDA to close loopholes that keep generic drugs off the market, they said in a recent letter to FDA…

Continue ReadingSen. Warren, Rep. Jayapal Ask FDA to Close Loopholes That Keep Generics Off the Market

JAMA Analysis Shows Expedited Programs Shave Up to 2 Years Off Development, Review

  • Post author:PacConAdmin
  • Post published:August 31, 2023
  • Post category:Uncategorized

FDA’s expedited regulatory programs cut up to two years off both clinical development and approval times for more than half of the drugs approved from 2015-2022, according to a new…

Continue ReadingJAMA Analysis Shows Expedited Programs Shave Up to 2 Years Off Development, Review

Hamilton Medical Sees Class I Recall for Ventilators That Stop Without Notice

  • Post author:PacConAdmin
  • Post published:August 31, 2023
  • Post category:Uncategorized

The FDA has deemed Hamilton Medical’s recall of certain of its ventilators as class I, the most serious type of recall as use the device may lead to serious injury…

Continue ReadingHamilton Medical Sees Class I Recall for Ventilators That Stop Without Notice

Outlook’s Lytenava Gets CRL for Manufacturing Issues, More Evidence

  • Post author:PacConAdmin
  • Post published:August 31, 2023
  • Post category:Uncategorized

The FDA issued Outlook Therapeutics a complete response letter (CRL) on its BLA for Lytenava (bevacizumab), an investigational ophthalmic formulation under development to treat wet age-related macular degeneration (AMD). Source:…

Continue ReadingOutlook’s Lytenava Gets CRL for Manufacturing Issues, More Evidence

Companies Regulated by CDRH Near Top of FDA Ombudsman’s Frequent Flyer List

  • Post author:PacConAdmin
  • Post published:August 30, 2023
  • Post category:Uncategorized

After inquiries about food, the FDA Office of the Ombudsman hears most often from device companies — because there are more small companies in that area of the industry —…

Continue ReadingCompanies Regulated by CDRH Near Top of FDA Ombudsman’s Frequent Flyer List

Novo Nordisk Buys Another Obesity Drugmaker as Wegovy Fever Continues to Rise

  • Post author:PacConAdmin
  • Post published:August 30, 2023
  • Post category:Uncategorized

Novo Nordisk has acquired Embark Biotech, as the larger Danish drugmaker looks to expand its blockbuster obesity drug portfolio in the wake of surging economic demand and rising market shortages…

Continue ReadingNovo Nordisk Buys Another Obesity Drugmaker as Wegovy Fever Continues to Rise

Quick Notes for Aug. 30, 2023

  • Post author:PacConAdmin
  • Post published:August 30, 2023
  • Post category:Uncategorized

Our coverage spans a bone graft product that caused a tuberculosis infection, a subcutaneous cancer treatment, a warning letter for an eye drop manufacturer, 300 higher risk patients with a…

Continue ReadingQuick Notes for Aug. 30, 2023

Three FDA Guidances: Using Real-World Data in Observational Studies and DSCSA

  • Post author:PacConAdmin
  • Post published:August 30, 2023
  • Post category:Uncategorized

The FDA issued three final guidances on Wednesday, one on the use of real-world data (RWD) in noninterventional (observational) studies and two on the Drug Supply Chain Security Act (DSCSA).…

Continue ReadingThree FDA Guidances: Using Real-World Data in Observational Studies and DSCSA

Meeting Planner — Week of Aug. 28, 2023

  • Post author:PacConAdmin
  • Post published:August 30, 2023
  • Post category:Uncategorized

Upcoming events in the coming weeks include ten FDA advisory committee meetings as well as the GMP Quality Management vSummit, the WCG MAGI@Home Clinical Research Conference 2023, the 18th Annual…

Continue ReadingMeeting Planner — Week of Aug. 28, 2023
  • 1
  • 2
  • 3
  • 4
  • …
  • 12
  • Go to the next page

Stay Connected

Keep up with the latest news & insights.

Contact Us

Phone:
+1 858-605-5882
Fax:
+1 858-605-5916
Email:
info@biolegacyresearch.com
Mail:
6042 Cornerstone Court W
Suite E
San Diego, CA 92121
Social::
© 2025 BioLegacy Research. All rights reserved.
BioLegacy research is a PharmaLegacy Laboratories company